Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Uterine Cervical Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Liver Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Triple Negative Breast Neoplasms 1 Tobacco Use Disorder 1 Squamous Cell Carcinoma of Head and Neck 1 Smoking 1 Sarcoma 1 Recurrence 1 Precancerous Conditions 1 Pharyngeal Neoplasms 1 Peritoneal Neoplasms 1 Paranasal Sinus Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Laryngeal Neoplasms 1 Glioblastoma 1 Colonic Neoplasms 1 Breast Neoplasms 1 Biomarker Change Linked to Breast Cancer 1

Interventions

pembrolizumab 44 Nivolumab 29 Gemcitabine 28 Paclitaxel 19 Cisplatin 18 Ipilimumab 15 Carboplatin 14 Cyclophosphamide 13 Capecitabine 12 Dexamethasone 10 Bevacizumab 10 cemiplimab 9 Irinotecan 9 Docetaxel 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 spartalizumab 8 Pemetrexed 8 Sorafenib 7 Rituximab 7 Cetuximab 7 fludarabine 6 Temozolomide 6 Taxes 6 Radiotherapy 6 Leucovorin 6 Fluorouracil 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × Celecoxib × Clear all

NCT00581971 2013-04-25

RAD0201

University of Alabama at Birmingham

Phase 1/2 Completed

30 enrolled 8 charts

Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡